Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
Portfolio Pulse from Vandana Singh
Pliant Therapeutics Inc (NASDAQ:PLRX) announced positive data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints, demonstrating that bexotegrast was well tolerated and its plasma concentrations increased with dose. The trial's exploratory efficacy endpoints showed bexotegrast reduced both ELF scores and PRO-C3 levels at Week 12 at all doses relative to placebo. PLRX shares were up 13.10% at $16.48 on the last check Tuesday.
September 26, 2023 | 6:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' successful trial results for bexotegrast in liver disease patients have led to a 13.10% increase in its share price.
The positive trial results indicate that Pliant Therapeutics' bexotegrast is effective in treating liver disease, which could potentially lead to increased sales and revenue for the company. This positive news has already resulted in a significant increase in the company's share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100